Evuzamitide Detects Cardiac Amyloidosis Across Subtypes
The prospective Phase 3 REVEAL study found that iodine-124 evuzamitide PET/CT detected cardiac amyloidosis with 94% sensitivity and 86% specificity by majority read in 170 analyzed patients. Negative and positive predictive values were 94%…
